Wow! Articles like this one definitely puts things into perspective. If a company like J&J is willing to pay that kind of money for assets with considerable risks, then I can see why GC and his advisors are being patient.

ABMS has a product that will launch real soon...and the market is HUGE! Even if we don't consider Elto and MANF, Lympro alone will get at least one BP willing to write a big check! Count on it.